NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
5 trialsNCT04433182 2025-08-08
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
NCT04750941 2025-03-04
Study of Copanlisib and Ketogenic Diet
Columbia University
Phase 2 Terminated
NCT04155840 2022-04-11
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of Washington
Phase 2 Terminated
NCT02455297 2017-10-02
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Bayer
Phase 2 Terminated